Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients

Table 3 Factors at 12 wk influencing hepatitis B e antigen seroconversion in treated patients evaluated using univariate and multivariate analyses n (%)

Parameter	RS	Univariate analysis	P value	Multivariate analysis	P value
		OR (95%CI)		OR (95%CI)
ALT > 7 × ULN	8 (61.5)	3.90 (1.20-12.66)	0.024
HBV DNA ≤ 5 log10 copies/mL	31 (53.4)	5.24 (2.48-11.06)	< 0.001
HBsAg ≤ 10000 IU/mL	41 (48.2)	8.70 (3.39-22.34)	< 0.001
HBeAg ≤ 250 S/CO	44 (55.7)	27.24 (7.89-94.09)	< 0.001	10.90 (2.63-45.27)	0.001
anti-HBc > 11.8 S/CO	23 (47.9)	2.88 (1.39-5.96)	0.005	3.72 (1.41-9.84)	0.008
Decline ALT > 3 × ULN	20 (40.0)	1.73 (0.84-3.55)	0.136
Decline HBV DNA > 1.5 log10 copies/mL	34 (48.6)	4.65 (2.18-9.93)	< 0.001
Decline HBsAg > 0.5 log10 IU/mL	29 (55.8)	5.39 (2.55-11.42)	< 0.001
Decline HBeAg > 1 log10 S/CO	34 (66.7)	12.77 (5.60-29.14)	< 0.001	4.53 (1.59-12.91)	0.005
Decline anti-HBc > 0.5 S/CO	13 (40.6)	1.64 (0.53-5.07)	0.393

ALT: Alanine aminotransferase; ULN: Upper limit of normal; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBc: Antibody to hepatitis B core antigen; RS: Patients with HBeAg seroconversion.